Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.

NCT NCT05918302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Lead sponsor
Grupo Espanol de Tumores Neuroendocrinos
Phase
Phase 3
Overall status
Recruiting
Start date
October 27, 2023
Completion date
October 31, 2029
Enrollment
170 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

lung neuroendocrine neoplasm, neuroendocrine tumors, thymus neoplasms